# Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

> **NCT02750592** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 30 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

## Key facts

- **NCT ID:** NCT02750592
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-22
- **Primary completion:** 2017-07-05
- **Final completion:** 2018-05-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02750592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02750592, "Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02750592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*